-
Organ Repair and Regeneration During Ex Situ Dynamic Preservation: The Future is Nano. Transpl. Int. (IF 3.1) Pub Date : 2023-11-10 Nicholas Gilbo,Joris Blondeel,Jacques Pirenne,Renato Romagnoli,Giovanni Camussi,Diethard Monbaliu
Organ preservation and assessment with machine perfusion (MP) has provided transplant physicians with the ability to evaluate and select grafts suitable for transplantation. Nevertheless, the discard of organs considered too damaged still sustains the imbalance between donor organs supply and demands. Therefore, there is the pressing clinical need for strategies to repair and/or regenerate organs before
-
-
New Approaches to Manage Infections in Transplant Recipients: Report From the 2023 GTI (Infection and Transplantation Group) Annual Meeting. Transpl. Int. (IF 3.1) Pub Date : 2023-11-09 Alexandra Serris,Julien Coussement,Benoît Pilmis,Victoire De Lastours,Aurélien Dinh,François Parquin,Eric Epailly,Florence Ader,Olivier Lortholary,Emmanuel Morelon,Nassim Kamar,Edouard Forcade,David Lebeaux,Jérôme Dumortier,Filomena Conti,Agnes Lefort,Anne Scemla,Hannah Kaminski
-
Vitrification and Nanowarming. Is this the Future of Kidney Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-11-08 Sarah A Hosgood,Michael L Nicholson
-
Prolonging Preservation or Assessment of Organ Quality-What is Key? Transpl. Int. (IF 3.1) Pub Date : 2023-11-08 J Eden,P Dutkowski
-
Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use? Transpl. Int. (IF 3.1) Pub Date : 2023-11-07 Oriol Bestard,Hannah Kaminski,Lionel Couzi,Mario Fernández-Ruiz,Oriol Manuel
Utilizing assays that assess specific T-cell-mediated immunity against cytomegalovirus (CMV) holds the potential to enhance personalized strategies aimed at preventing and treating CMV in organ transplantation. This includes improved risk stratification during transplantation compared to relying solely on CMV serostatus, as well as determining the optimal duration of antiviral prophylaxis, deciding
-
A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection. Transpl. Int. (IF 3.1) Pub Date : 2023-11-07 Lukas K van Vugt,Marieke van der Zwan,Marian C Clahsen-van Groningen,Madelon van Agteren,Daphne M Hullegie-Peelen,Brenda C M De Winter,Marlies E J Reinders,Pedro Miranda Afonso,Dennis A Hesselink
Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejection therapy between 2012 and 2022 in our institution were investigated. Graft survival, graft function, lymphocyte depletion, serious infections, malignancies
-
Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy-Results of a Prospective Single-Center Trial. Transpl. Int. (IF 3.1) Pub Date : 2023-11-03 Louise Benning,Christian Morath,Annette Fink,Markus Rudek,Claudius Speer,Florian Kälble,Christian Nusshag,Jörg Beimler,Constantin Schwab,Rüdiger Waldherr,Martin Zeier,Caner Süsal,Thuong Hien Tran
Donor-derived cell-free DNA (dd-cfDNA) identifies allograft injury and discriminates active rejection from no rejection. In this prospective study, 106 kidney transplant recipients with 108 clinically indicated biopsies were enrolled at Heidelberg University Hospital between November 2020 and December 2022 to validate the clinical value of dd-cfDNA in a cohort of German patients. dd-cfDNA was quantified
-
Women Referred for Liver Transplant Are Less Likely to Be Transplanted Irrespective of Socioeconomic Status. Transpl. Int. (IF 3.1) Pub Date : 2023-11-02 Emmanouil Giorgakis,Martha M Estrada,Allison Wells,Mauricio Garcia Saenz de Sicilia,Matthew Deneke,Raj Patel,Gary Barone,Lyle Burdine,Mary K Rude
-
Sleepiness and Health-Related Quality of Life Among Kidney Transplant Recipients in a Low-Middle Income Country: A Cross-Sectional Study. Transpl. Int. (IF 3.1) Pub Date : 2023-11-01 Mayssaa Hoteit,Ahmad Al-Masry,Martine Elbejjani,Mabel Aoun,Rana Abu-Dargham,Walid Medawar,Hilal Abou Zeinab,Laila Farhood,Sahar H Koubar
This study aims to describe daytime sleepiness and health-related quality of life (HRQoL) among Lebanese kidney transplant (KT) recipients and to examine the medical, psychosocial and transplant factors related to them. It is a cross-sectional multi-center study involving KT recipients >18 years. Daytime sleepiness was assessed using ESS Questionnaire. HRQoL was measured using the SF-36 questionnaire
-
Importance and Potential of European Cross-Border Deceased Donor Organ Allocation Through FOEDUS-EOEO Platform. Transpl. Int. (IF 3.1) Pub Date : 2023-10-31 Andreas Elmer,Vera Valérie Lütolf,Claudia Carella,Franziska Beyeler,Nathalie Krügel,Libor Straka,Massimo Cardillo,Franz Immer
The FOEDUS-EOEO platform was relaunched in 2015 to allocate deceased donor organs across European borders when there are no suitable recipients in the donor's country. We analyzed organ offers from 01.06.2015-31.12.2021 and present the number of offers and transplants, and utilization as percentage of transplanted organs. 1,483 organs were offered, 287 were transplanted (19.4% utilization). Yearly
-
Donors With a Prior History of Cancer: Factors of Non-Utilization of Kidneys for Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-10-31 Wai H Lim,Eric Au,Armando Teixeira-Pinto,Esther Ooi,Helen Opdam,Jeremy Chapman,David W Johnson,John Kanellis,Christopher E Davies,Germaine Wong
Cancer transmission from deceased donors is an exceedingly rare but potentially fatal complication in transplant recipients. We aimed to quantify the likelihood of non-utilization of kidneys for transplantation from donors with a prior cancer history. We included all intended and actual deceased donors in Australia and New Zealand between 1989 and 2017. Association between prior cancer history and
-
Absolute Quantification of Donor-Derived Cell-Free DNA in Pediatric and Adult Patients After Heart Transplantation: A Prospective Study. Transpl. Int. (IF 3.1) Pub Date : 2023-10-30 Jens Böhmer,Carina Wasslavik,Daniel Andersson,Anders Ståhlberg,Marianne Jonsson,Håkan Wåhlander,Kristjan Karason,Jan Sunnegårdh,Staffan Nilsson,Julia Asp,Göran Dellgren,Anne Ricksten
In this prospective study we investigated a cohort after heart transplantation with a novel PCR-based approach with focus on treated rejection. Blood samples were collected coincidentally to biopsies, and both absolute levels of dd-cfDNA and donor fraction were reported using digital PCR. 52 patients (11 children and 41 adults) were enrolled (NCT03477383, clinicaltrials.gov), and 557 plasma samples
-
Validated Prognostic Scores to Predict Outcomes in ECLS-Bridged Patients to Lung Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-10-30 Eleonora Faccioli,Giulia Lorenzoni,Didier Schneiter,Andrea Dell'Amore,Sven Hillinger,Marco Schiavon,Claudio Caviezel,Dario Gregori,Federico Rea,Isabelle Opitz,Ilhan Inci
Selection of patients who may benefit from extracorporeal life support (ECLS) as a bridge to lung transplant (LTx) is crucial. The aim was to assess if validated prognostic scores could help in selecting patients who may benefit from ECLS-bridging predicting their outcomes. Clinical data of patients successfully ECLS-bridged to LTx from 2009 to 2021 were collected from two European centers. For each
-
Embracing the Wisdom of Ancient Greece in the Era of Personalized Medicine-Uncertainty, Probabilistic Reasoning, and Democratic Consensus. Transpl. Int. (IF 3.1) Pub Date : 2023-10-26 Maarten Naesens
Further improvements of outcome after solid organ transplantation will depend on our ability to integrate personalized medicine in clinical routine. Not only better risk stratification or improved diagnostics, also targeted therapies and predictive markers of treatment success are needed, as there is a virtual standstill in the development and implementation of novel therapies for prevention and treatment
-
Preferred Islet Delivery Device Characteristics and Implantation Strategies of Patients With Type 1 Diabetes. Transpl. Int. (IF 3.1) Pub Date : 2023-10-16 Maarten C Tol,Denise F A de Bont,Wouter P C Boon,Eelco J P de Koning,Aart A van Apeldoorn
Islet delivery devices (IDDs) offer potential benefits for islet transplantation and stem cell-based replacement in type 1 diabetes. Little is known about patient preferences regarding islet delivery device characteristics and implantation strategies. Patient preferences for IDDs and implantation strategies remain understudied. We invited patients, parents and caregivers to fill in an online questionnaire
-
Banff Digital Pathology Working Group: Image Bank, Artificial Intelligence Algorithm, and Challenge Trial Developments. Transpl. Int. (IF 3.1) Pub Date : 2023-10-16 Alton B Farris,Mariam P Alexander,Ulysses G J Balis,Laura Barisoni,Peter Boor,Roman D Bülow,Lynn D Cornell,Anthony J Demetris,Evan Farkash,Meyke Hermsen,Julien Hogan,Renate Kain,Jesper Kers,Jun Kong,Richard M Levenson,Alexandre Loupy,Maarten Naesens,Pinaki Sarder,John E Tomaszewski,Jeroen van der Laak,Dominique van Midden,Yukako Yagi,Kim Solez
The Banff Digital Pathology Working Group (DPWG) was established with the goal to establish a digital pathology repository; develop, validate, and share models for image analysis; and foster collaborations using regular videoconferencing. During the calls, a variety of artificial intelligence (AI)-based support systems for transplantation pathology were presented. Potential collaborations in a competition/trial
-
Telehealth Experience Among Liver and Kidney Transplant Recipients: A Mixed Methods Study. Transpl. Int. (IF 3.1) Pub Date : 2023-10-16 Dami Ko,Julia Dierker,Rebecca Stouff,Laura Senier
Telehealth has become widely available to solid organ transplant (SOT) recipients during the COVID-19 pandemic. While evidence suggests that telehealth serves as an acceptable alternative for most SOT recipients, their satisfaction and its context remain unclear. This study used a mixed methods approach to investigate the perspectives of SOT recipients (i.e., liver, kidney, and simultaneous liver-kidney)
-
Three Decades Single Center Experience of Airway Complications After Lung Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-10-16 R van Pel,C T Gan,W van der Bij,E A M Verschuuren,J P A van Gemert,C Van De Wauwer,M E Erasmus,D J Slebos
Post lung transplantation airway complications like necrosis, stenosis, malacia and dehiscence cause significant morbidity, and are most likely caused by post-operative hypo perfusion of the anastomosis. Treatment can be challenging, and airway stent placement can be necessary in severe cases. Risk factors for development of airway complications vary between studies. In this single center retrospective
-
The Role of the Duffy Blood Group Antigens in Renal Transplantation and Rejection. A Mini Review. Transpl. Int. (IF 3.1) Pub Date : 2023-10-13 Dana Hariri,Jozsef Bordas,Matthew Elkins,Brian Gallay,Zhanna Spektor,Reut Hod-Dvorai
Finding a compatible donor for kidney transplant candidates requires overcoming immunological barriers such as human leukocyte antigens (HLA) compatibility and ABO compatibility. Emerging data suggest a role for red blood cell antigens (RCA) in renal transplant outcomes. The incidence of RCA alloimmunization is high in chronically transfused individuals, such as end stage renal disease patients, but
-
48 h Normothermic Machine Perfusion With Urine Recirculation for Discarded Human Kidney Grafts. Transpl. Int. (IF 3.1) Pub Date : 2023-10-13 Franka Messner,Afschin Soleiman,Dietmar Öfner,Hannes Neuwirt,Stefan Schneeberger,Annemarie Weissenbacher
Normothermic machine perfusion (NMP) has reshaped organ preservation in recent years. In this preclinical study, prolonged normothermic perfusions of discarded human kidney grafts were performed in order to investigate perfusion dynamics and identify potential quality and assessment indicators. Five human discarded kidney grafts were perfused normothermically (37°C) for 48 h using the Kidney Assist
-
Assessment of Donor Derived Cell Free DNA (dd-cfDNA) at Surveillance and at Clinical Suspicion of Acute Rejection in Renal Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-10-13 Evangelos Mantios,Vassilis Filiopoulos,Pantelis Constantoulakis,George Liapis,Angeliki Vittoraki,Silvia Casas,Smaragdi Marinaki,John N Boletis
In our prospective, unicenter cohort study, we collected blood samples from 30 newly kidney transplanted patients, at month 1, 2, 3, and 5 for dd-cfDNA analysis, along with creatinine/eGFR and DSA monitoring, and from 32 patients who underwent an indication biopsy and whose dd-cfDNA levels were measured at the time of biopsy and 1 month afterwards. Fourteen of 32 (43.8%) patients in the biopsy group
-
Performance of Scores Predicting Adverse Outcomes in Procurement Kidney Biopsies From Deceased Donors With Organs of Lower-Than-Average Quality. Transpl. Int. (IF 3.1) Pub Date : 2023-10-12 Florian G Scurt,Angela Ernst,Carl-Ludwig FischerFröhlich,Anke Schwarz,Jan U Becker,Christos Chatzikyrkou
Several scores have been devised for providing a prognosis of outcomes after kidney transplantation. This study is a comprehensive test of these scores in a cohort of deceased donors with kidneys of lower-than-average quality and procurement biopsies. In total, 15 scores were tested on a retrospective cohort consisting of 221 donors, 223 procurement biopsies, and 223 recipient records for performance
-
New Treatment Options for Refractory/Resistant CMV Infection. Transpl. Int. (IF 3.1) Pub Date : 2023-10-12 Carla Simone Walti,Nina Khanna,Robin K Avery,Ilkka Helanterä
Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain one of the most common complications after solid organ transplantation (SOT). CMV infection may fail to respond to standard first- and second-line antiviral therapies with or without the presence of antiviral resistance to these therapies. This failure to respond after 14 days of appropriate treatment is referred
-
Adherence to Pharmacotherapies After Heart Transplantation in Relation to Multimorbidity and Socioeconomic Position: A Nationwide Register-Based Study. Transpl. Int. (IF 3.1) Pub Date : 2023-10-11 Rikke E Mols,István Bakos,Brian B Løgstrup,Erzsébet Horváth-Puhó,Finn Gustafsson,Hans Eiskjær
No studies have examined the impact of multimorbidity and socioeconomic position (SEP) on adherence to the pharmacological therapies following heart transplantation (HTx). Using nationwide Danish registers, we tested the hypothesis that multimorbidity and SEP affect treatment patterns and adherence to pharmacological therapies in first-time HTx recipients. Pharmacological management included cost-free
-
Islets-on-Chip: A Tool for Real-Time Assessment of Islet Function Prior to Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-10-11 Matthieu Raoux,Sandrine Lablanche,Manon Jaffredo,Antoine Pirog,Pierre-Yves Benhamou,Fanny Lebreton,Anne Wojtusciszyn,Domenico Bosco,Thierry Berney,Sylvie Renaud,Jochen Lang,Bogdan Catargi
Islet transplantation improves metabolic control in patients with unstable type 1 diabetes. Clinical outcomes have been improving over the last decade, and the widely used beta-score allows the evaluation of transplantation results. However, predictive pre-transplantation criteria of islet quality for clinical outcomes are lacking. In this proof-of-concept study, we examined whether characterization
-
Should Physicians Be Permitted to Refuse Follow-Up Care to Patients Who Have Received an Organ Transplant Through Organ Trafficking? Transpl. Int. (IF 3.1) Pub Date : 2023-10-06 Yoshiyuki Takimoto
In 2018, the Istanbul Declaration stated that organ transplantation via organ trafficking is a crime. Since then, the number of medical institutions in Japan who refuse follow-up care to patients who have undergone unethical organ transplantation overseas has been gradually increasing. Deterring transplant tourism involving organ trafficking is an issue that must be addressed by the government, medical
-
Impact of Previous Conventional Cardiac Surgery on the Clinical Outcomes After Heart Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-10-03 Jeng-Wei Chen,Heng-Wen Chou,Nai-Kuan Chou,Chih-Hsien Wang,Nai-Hsin Chi,Shu-Chien Huang,Hsi-Yu Yu,Yih-Sharng Chen,Ron-Bin Hsu
The impact of the type, purpose, and timing of prior surgery on heart transplantation (HT) remains unclear. This study investigated the influence of conventional cardiac surgery (PCCS) on HT outcomes. This study analyzed HTs performed between 1999 and 2019 at a single institution. Patients were categorized into two groups: those with and without PCCS. Short-term outcomes, including post-transplant
-
Excess Mortality in Kidney and Kidney-Pancreas Transplant Recipients in the COVID-19 Pandemic in Portugal-A Cohort Study. Transpl. Int. (IF 3.1) Pub Date : 2023-09-29 Miguel T Coimbra,José A T S Francisco,Joana C Freitas,Renata V Carvalho,Sara R B Vilela,Catarina I C D Ribeiro,José L C S L Silvano,Sofia Pedroso,Manuela Almeida,La Salete Martins,Jorge Malheiro
The COVID-19 pandemic increased morbidity and mortality worldwide, particularly in the Kidney and Kidney-Pancreas Transplant Recipient (KTR/KPTR) population. Aiming at assessing the absolute and relative excess mortality (EM) in a Portuguese KTR/KPTR cohort, we conducted a retrospective observational study of two KTR/KPTRs cohorts: cohort 1 (P1; n = 2,179) between September/2012 and March/2020; cohort
-
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement. Transpl. Int. (IF 3.1) Pub Date : 2023-09-29 M Carbone,A Della Penna,C Mazzarelli,E De Martin,C Villard,A Bergquist,P D Line,J M Neuberger,S Al-Shakhshir,P J Trivedi,U Baumann,L Cristoferi,J Hov,B Fischler,N H Hadzic,D Debray,L D'Antiga,N Selzner,L S Belli,S Nadalin
Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines' Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical
-
Breaking Barriers and Bridging Gaps: Advancing Diversity, Equity, and Inclusion in Kidney Transplant Care for Black and Hispanic Patients in the United States. Transpl. Int. (IF 3.1) Pub Date : 2023-09-27 Chi Zhang,Amit K Mathur
Kidney transplantation offers better mortality and quality of life outcomes to patients with end-stage renal failure compared to dialysis. Specifically, living donor kidney transplantation is the best treatment for end-stage renal disease, since it offers the greatest survival benefit compared to deceased donor kidney transplant or dialysis. However, not all patients from all racial/ethnic backgrounds
-
The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time. Transpl. Int. (IF 3.1) Pub Date : 2023-09-27 Lorenzo Piemonti,Hanne Scholz,Dide de Jongh,Julie Kerr-Conte,Aart van Apeldoorn,James A M Shaw,Marten A Engelse,Eline Bunnik,Markus Mühlemann,Karolina Pal-Kutas,William E Scott,Jérémy Magalon,Patrick Kugelmeier,Ekaterine Berishvili
The field of transplantation has witnessed the emergence of Advanced Therapy Medicinal Products (ATMPs) as highly promising solutions to address the challenges associated with organ and tissue transplantation. ATMPs encompass gene therapy, cell therapy, and tissue-engineered products, hold immense potential for breakthroughs in overcoming the obstacles of rejection and the limited availability of donor
-
Validation of Igls Criteria for Islet Transplant Functional Status Using Person-Reported Outcome Measures in a Cross-Sectional Study. Transpl. Int. (IF 3.1) Pub Date : 2023-09-26 Zoe Bond,Saffron Malik,Ayat Bashir,Rachel Stocker,Jocelyn Buckingham,Jane Speight,James A M Shaw
Associations between islet graft function and well-being in islet transplant recipients requiring exogenous insulin remain unclear. This cross-sectional analysis compared person-reported outcome measures in 15 adults with type 1 diabetes whose islet transplants were classified according to Igls criteria as "Good" (n = 5), "Marginal" (n = 4) and "Failed" (n = 6) graft function. At a mean of 6.2 years
-
ABO Incompatible Kidney Transplantation Without B-cell Depletion is Associated With Increased Early Acute Rejection: A Single-Center Australian Experience. Transpl. Int. (IF 3.1) Pub Date : 2023-09-20 Jonathan M Bleasel,Susan S Wan,Steven J Chadban,Tracey Ying,David M Gracey,Leyla J Aouad,Qian-Ao Chen,Mike Utsiwegota,Jane Mawson,Kate R Wyburn
We performed a single-center retrospective cohort study of 66 consecutive ABO incompatible kidney transplants (ABOiKT) performed without B-cell depleting therapy. Outcomes were compared to an earlier era performed with rituximab (n = 18) and a contemporaneous cohort of ABO compatible live donor transplants (ABOcKT). Acute rejection within 3 months of transplant was significantly more common after rituximab-free
-
Mechanical Power Density Predicts Prolonged Ventilation Following Double Lung Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-09-20 Alessandro Ghiani,Nikolaus Kneidinger,Claus Neurohr,Sandra Frank,Ludwig Christian Hinske,Christian Schneider,Sebastian Michel,Michael Irlbeck
Prolonged mechanical ventilation (PMV) after lung transplantation poses several risks, including higher tracheostomy rates and increased in-hospital mortality. Mechanical power (MP) of artificial ventilation unifies the ventilatory variables that determine gas exchange and may be related to allograft function following transplant, affecting ventilator weaning. We retrospectively analyzed consecutive
-
Clinical Translation of Bio-Artificial Pancreas Therapies: Ethical, Legal and Psychosocial Interdisciplinary Considerations and Key Recommendations. Transpl. Int. (IF 3.1) Pub Date : 2023-09-18 Dide de Jongh,Rebecca L Thom,Antonia J Cronin,Eline M Bunnik,Emma K Massey
The field of regenerative medicine offers potential therapies for Type 1 Diabetes, whereby metabolically active cellular components are combined with synthetic medical devices. These therapies are sometimes referred to as "bioartificial pancreases." For these emerging and rapidly developing therapies to be clinically translated to patients, researchers must overcome not just scientific hurdles, but
-
Considering ABO Incompatible Living Donor Kidney Transplantation Before Deceased Donor Kidney Transplantation in Children: A Letter to the Editor. Transpl. Int. (IF 3.1) Pub Date : 2023-09-18 Alicia Paessler,Jelena Stojanovic
-
-
Impact of Calcineurin Inhibitor-Based Immunosuppression Maintenance During the Dialysis Period After Kidney Transplant Failure on the Next Kidney Graft Outcome: A Retrospective Multicenter Study With Propensity Score Analysis. Transpl. Int. (IF 3.1) Pub Date : 2023-09-15 Juliette Noelle,Valentin Mayet,Céline Lambert,Lionel Couzi,Bertrand Chauveau,Antoine Thierry,Laure Ecotière,Dominique Bertrand,Charlotte Laurent,Richard Lemal,Clarisse Grèze,Marine Freist,Anne-Elisabeth Heng,Paul-Olivier Rouzaire,Cyril Garrouste
The impact of immunosuppressive therapy (IS) strategies after kidney transplant failure (KTF) on potential future new grafts is poorly established. We assessed the potential benefit of calcineurin inhibitor (CNI)-based IS maintenance throughout the dialysis period on the outcome of the second kidney transplant (KT). We identified 407 patients who underwent a second KT between January 2008 and December
-
When There is No Guidance From the Guidelines: Renal Transplantation in Recipients With Class III Obesity. Transpl. Int. (IF 3.1) Pub Date : 2023-09-15 Hannah Gillespie,Stephen O'Neill,Rebecca M K Curtis,Chris Callaghan,Aisling E Courtney
Whilst renal transplantation is the optimal treatment for many patients with end-stage kidney disease, the latest international guidelines are unable to make recommendations for the management of patients with end-stage kidney stage kidney disease and Class III Obesity (BMI ≥40 kg/m2). Data on all adult patients receiving a kidney-only-transplant in the UK between 2015-2021 were analysed from a prospectively
-
European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma. Transpl. Int. (IF 3.1) Pub Date : 2023-09-14 Marco Petrus Adrianus Wilhelmus Claasen,Dimitri Sneiders,Yannick Sebastiaan Rakké,René Adam,Sherrie Bhoori,Umberto Cillo,Constantino Fondevila,Maria Reig,Gonzalo Sapisochin,Parissa Tabrizian,Christian Toso
Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients
-
Liver Inclusion Appears to Be Protective Against Graft Loss-Due-to Chronic But Not Acute Rejection Following Intestinal Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-09-14 Rodrigo Vianna,Jeffrey J Gaynor,Gennaro Selvaggi,Ahmed Farag,Jennifer Garcia,Akin Tekin,Marina M Tabbara,Gaetano Ciancio
In intestinal transplantation, while other centers have shown that liver-including allografts have significantly more favorable graft survival and graft loss-due-to chronic rejection (CHR) rates, our center has consistently shown that modified multivisceral (MMV) and full multivisceral (MV) allografts have significantly more favorable acute cellular rejection (ACR) and severe ACR rates compared with
-
Association Between Pre-Transplant Oral Health and Post-Liver Transplant Complications. Transpl. Int. (IF 3.1) Pub Date : 2023-09-12 Annika Emilia Olander,Jaana Helenius-Hietala,Arno Nordin,Johanna Savikko,Hellevi Ruokonen,Fredrik Åberg
Oral disease is linked with systemic inflammation and various systemic conditions, including chronic liver disease. Liver transplantation (LT) candidates often need dental infection focus eradication, and after LT, there is high risk of many inflammation-related complications. We studied whether pre-LT dental status is associated with the occurrence of post-LT complications. This study included 225
-
A Multi-Step Precision Pathway for Predicting Allograft Survival in Heterogeneous Cohorts of Kidney Transplant Recipients. Transpl. Int. (IF 3.1) Pub Date : 2023-09-12 Yunwei Zhang,Danny Deng,Samuel Muller,Germaine Wong,Jean Yee Hwa Yang
Accurate prediction of allograft survival after kidney transplantation allows early identification of at-risk recipients for adverse outcomes and initiation of preventive interventions to optimize post-transplant care. Many prediction algorithms do not model cohort heterogeneity and may lead to inaccurate assessment of longer-term graft outcomes among minority groups. Using data from a national Australian
-
Approaching the Families of Potential Deceased Organ Donors: An Overview of Regulations and Practices in Council of Europe Member States. Transpl. Int. (IF 3.1) Pub Date : 2023-09-12 Sándor Mihály,Anikó Smudla,Beatriz Dominguez-Gil,Alicia Pérez,Francesco Procaccio,Emanuele Cozzi,Marta López Fraga,Danica Avsec,Axel Rahmel,John Forsythe,Franz Immer,Janis Jushinskis,Alex Manara
The primary aim of this study was to describe regulations and practices concerning the family approach to discuss donation, specifically after the neurological determination of death, one of the most challenging steps in the donation pathway. A secondary objective was to assess the impact of legislation on consent rates for organ donation. The Council of Europe surveyed 39 member states about national
-
Application of Intestinal Barrier Molecules in the Diagnosis of Acute Cellular Rejection After Intestinal Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-09-08 Yun Chen,Sheng-Hong Tseng,Chih-Yen Chen,Ya-Hui Tsai
Diagnosing acute rejection after intestinal transplantation currently heavily relies on histopathological analysis of graft biopsies. However, the invasive risks associated with ileoscopic examination and the inaccessibility for biopsy after ileostomy closure hinder real-time detection of rejection responses. Molecules comprising the intestinal barrier have been identified as physiological and molecular
-
Preclinical Study of DCD and Normothermic Perfusion for Visceral Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-09-08 Javier Serradilla,Ane Miren Andrés Moreno,Paloma Talayero,Paula Burgos,Mariana Machuca,Onys Camps Ortega,María Teresa Vallejo,Francisco Javier Rubio Bolívar,Alba Bueno,Alba Sánchez,Cristina Zambrano,Carlos Andrés De la Torre Ramos,Olaia Rodríguez,Carlota Largo,Pilar Serrano,Gerardo Prieto Bozano,Esther Ramos,Manuel López Santamaría,Pablo Stringa,Francisco Hernández
Considering recent clinical and experimental evidence, expectations for using DCD-derived intestines have increased considerably. However, more knowledge about DCD procedure and long-term results after intestinal transplantation (ITx) is needed. We aimed to describe in detail a DCD procedure for ITx using normothermic regional perfusion (NRP) in a preclinical model. Small bowel was obtained from pigs
-
External Validation of Toulouse-Rangueil eGFR12 Prediction Model After Living Donor Nephrectomy. Transpl. Int. (IF 3.1) Pub Date : 2023-09-07 Suhani S Patel,Bonnie E Lonze,Teresa Po-Yu Chiang,Fawaz Al Ammary,Dorry L Segev,Allan B Massie
Decreased postdonation eGFR is associated with a higher risk of ESRD after living kidney donation, even when accounting for predonation characteristics. The Toulouse-Rangueil model (TRM) estimates 12 month postdonation eGFR (eGFR12) to inform counseling of candidates for living donation. The TRM was validated in several single-center European cohorts but has not been validated in US donors. We assessed
-
Refusal Rates to Organ Donation in Intensive Care Units Among Immigrant Populations in Italy. Transpl. Int. (IF 3.1) Pub Date : 2023-09-07 Alessandra Agnese Grossi,Francesca Puoti,Umberto Maggiore,Massimo Cardillo
-
Beyond the Concepts of Elder and Marginal in DCD Liver Transplantation: A Prospective Observational Matched-Cohort Study in the Italian Clinical Setting. Transpl. Int. (IF 3.1) Pub Date : 2023-09-07 Guido Fallani,Alberto Stocco,Antonio Siniscalchi,Marta Velia Antonini,Adriano Pasquale Stella,Alessio Amato,Enrico Prosperi,Laura Turco,Maria Cristina Morelli,Matteo Cescon,Matteo Ravaioli
Donation after circulatory determination of death (DCD) is a valuable strategy to increase the availability of grafts for liver transplantation (LT). As the average age of populations rises, the donor pool is likely to be affected by a potential increase in DCD donor age in the near future. We conducted a prospective cohort study to evaluate post-transplantation outcomes in recipients of grafts from
-
Vigilance Data in Organ Donation and Solid Organ Transplantation in Germany: Six Years of Experience 2016-2022. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Klaus Böhler,Axel Rahmel,Ana Paula Barreiros
The reporting of serious adverse events (SAE) and serious adverse reactions (SAR) is an essential part of an effective vigilance and surveillance system (V&S) in organ donation and transplantation. All SAE and SAR reported to the German organ procurement organization (DSO) between 2016 and 2022 were analyzed. In case of a possible transmission of a disease to one or more recipients, an assessment of
-
Banff Human Organ Transplant Consensus Gene Panel for the Detection of Antibody Mediated Rejection in Heart Allograft Biopsies. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Alessia Giarraputo,Guillaume Coutance,Olivier Aubert,Marny Fedrigo,Fariza Mezine,Dina Zielinski,Michael Mengel,Patrick Bruneval,Jean-Paul Duong van Huyen,Annalisa Angelini,Alexandre Loupy
The molecular refinement of the diagnosis of heart allograft rejection based on whole-transcriptome analyses faces several hurdles that greatly limit its widespread clinical application. The targeted Banff Human Organ Transplant gene panel (B-HOT, including 770 genes of interest) has been developed to facilitate reproducible and cost-effective gene expression analysis of solid organ allografts. We
-
Improved Quality of Life Among Chronic Pancreatitis Patients Undergoing Total Pancreatectomy With Islet Autotransplantation-Single Center Experience With Large Cohort of Patients. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Mariagrazia Coluzzi,Morihito Takita,Giovanna Saracino,Abdul Rub Hakim Mohammed,Carly M Darden,Giuliano Testa,Ernest Beecherl,Nicholas Onaca,Bashoo Naziruddin
Total pancreatectomy with islet autotransplantation (TPIAT) is the treatment of choice to preserve pancreatic endocrine function, alleviate pain, and improve quality of life (QoL) when other strategies are ineffective for chronic pancreatitis (CP) patients. This study utilized pancreatic disease-specific surveys developed by the European Organisation for Research and Treatment of Cancer (EORTC) to
-
The Effect of Continuous Liver Normothermic Machine Perfusion on the Severity of Histological Bile Duct Injury. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Nicholas Gilbo,Desley Neil,Rebecca Brais,Steffen Fieuws,Letizia Lo Faro,Peter Friend,Rutger Ploeg,Diethard Monbaliu
Static Cold Storage (SCS) injures the bile duct, while the effect of Normothermic Machine Perfusion (NMP) is unknown. In a sub-study of the COPE trial on liver NMP, we investigated the impact of preservation type on histological bile duct injury score (BDIS). Transplants with at least one bile duct biopsy, either at end of preservation or 1 h post-reperfusion, were considered. BDIS was determined by
-
All Expanded Criteria Donor Kidneys are Equal But are Some More Equal Than Others? A Population-Cohort Analysis of UK Transplant Registry Data. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Kamlesh Patel,Anna Brotherton,Daoud Chaudhry,Felicity Evison,Thomas Nieto,Dilan Dabare,Adnan Sharif
Survival outcomes for kidney transplant candidates based on expanded criteria donor (ECD) kidney type is unknown. A retrospective cohort study was undertaken of prospectively collected registry data of all waitlisted kidney failure patients receiving dialysis in the United Kingdom. All patients listed for their first kidney-alone transplant between 2000-2019 were included. Treatment types included;
-
Excellence in Organ Utilisation-A Quantitative and Qualitative Evidence Base for a New Approach in the UK. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Claire Williment,Jessica Jones,John Forsythe,Lisa Mumford,Stephen Powis
The Department of Health and Social Care in England established an Organ Utilisation Group, to collate and analyse evidence regarding the organ transplantation care pathway, make recommendations on how to reduce inequity of access, make the best use of available resources, and drive innovation in organ transplantation. The group consulted with national and international experts and stakeholders, sought
-
Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Alessandra Francica,Antonio Loforte,Matteo Attisani,Massimo Maiani,Attilio Iacovoni,Teodora Nisi,Marina Comisso,Amedeo Terzi,Michele De Bonis,Igor Vendramin,Massimo Boffini,Francesco Musumeci,Giovanni Battista Luciani,Mauro Rinaldi,Davide Pacini,Francesco Onorati
Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events in patients supported by HVAD and HeartMate3 (HM3). From 2010 to 2022, the MIRAMACS Italian Registry enrolled
-
Impact of Hepatitis E Virus Screening in the UK Deceased Organ Donor Population. Transpl. Int. (IF 3.1) Pub Date : 2023-09-04 Ines Ushiro-Lumb,John Forsythe,Becky Haywood,Christie Geoghegan,Victoria Maddox,Samreen Ijaz,Derek Manas,Douglas Thorburn
Universal Hepatitis E Virus (HEV) screening of deceased organ donors was implemented by the UK national organ procurement organisation in October 2017. Donor testing for HEV infection is done post-transplant; detection of HEV ribonucleic acid (RNA) in donor plasma is therefore not a contra-indication for organ donation, with the result being used to inform recipient management. Immediate post-transplant
-
Development of a Radiomics-Based Model to Predict Graft Fibrosis in Liver Transplant Recipients: A Pilot Study. Transpl. Int. (IF 3.1) Pub Date : 2023-09-01 Fakhar Ali Qazi Arisar,Emmanuel Salinas-Miranda,Hamideh Ale Ali,Katherine Lajkosz,Catherine Chen,Amirhossein Azhie,Gerard M Healy,Dominik Deniffel,Masoom A Haider,Mamatha Bhat
Liver Transplantation is complicated by recurrent fibrosis in 40% of recipients. We evaluated the ability of clinical and radiomic features to flag patients at risk of developing future graft fibrosis. CT scans of 254 patients at 3-6 months post-liver transplant were retrospectively analyzed. Volumetric radiomic features were extracted from the portal phase using an Artificial Intelligence-based tool
-
Pancreatic Allograft Thrombosis: Implementation of the CPAT-Grading System in a Retrospective Series of Simultaneous Pancreas-Kidney Transplantation. Transpl. Int. (IF 3.1) Pub Date : 2023-08-31 Palmina Petruzzo,Haixia Ye,Claudia Sardu,Olivier Rouvière,Fanny Buron,Jullien Crozon-Clauzel,Xavier Matillon,Jean Kanitakis,Emmanuel Morelon,Lionel Badet
Pancreatic graft thrombosis (PAT) is a major surgical complication, potentially leading to graft loss. The recently proposed Cambridge Pancreas Allograft Thrombosis (CPAT) grading system provides diagnostic, prognostic and therapeutic recommendations. The aim of the present study was to retrospectively assess computed tomography angiography (CTA) examinations performed routinely in simultaneous pancreas-kidney